

Substitute for Form PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/739,933
Filing Date	December 18, 2000
First Named Inventor	REID, James Steven
Art Unit	1625
Examiner Name	ANDRES, Janet L.
Attorney Docket Number	E8019-00001

Sheet 1 of 2

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DEFEO-JONES, D., et al., "Structure-Function Analysis of Synthetic and Recombinant Derivatives of Transforming Growth Factor Alpha", Molecular & Cellular Biology (1988); 8(8):2999-3007	
		FALLON, J. H., "Growth Factors in the Basal Ganglia", The British Library - "The world's knowledge", (1986) pp 247-260	
		FALLON, J. H., et al., "Localization of Cells Containing Transforming Growth Factor- $\alpha$ Precursor Immunoreactivity in the Basal Ganglia of the Adult Rat Brain", Growth Factors; 1990, 2:241-250	
		FALLON, J. H., et al., "Functional Implications of the Anatomical Localization of Neurotrophic Factors", Neurotrophic Factors, (Loughlin, S. E. & Fallon, J. H., Eds) 1993 Academic Press, New York, pp. 1-24	
		LOUGHLIN, S. E., et al., "Transforming Growth Factor Alpha: A Potential Role in the Efficacy of Intrastriatal Transplants", (1992) Soc. Neurosci. Abs	
		LOUGHLIN, S. E., et al., "Efficacy of Intrastriatal Transplants: Role of Trophic Factors", The Basal Ganglia IV, (Percheron, G., et al., Eds) 1994, Plenum Press, New York, pp. 205-212	
		LOUGHLIN, S. E., et al., "Striatal Transforming Growth Factor Alpha: Plasticity of Expression and Effects of Infusions of Dopaminergic Afferents", (1993) Soc. Neurosci. Abs.	
		LOUGHLIN, S. E., et al., "6-OHDA lesion and TGF $\alpha$ infusion-induced plasticity in the nigrostriatal dopamine system -- Tracing changes with markers for neurodegeneration", (1995) Soc. Neurosci. Abs.	
		PEZZOLI, G., et al., "Intraventricular Infusion of Epidermal Growth Factor Restores Dopaminergic Pathway in Hemiparkinsonian Rats", Movement Disorders (1991); 6(4):291-287	
		REID, S., et al., "Tyrosine Hydroxylase Immunoreactive Cells in Adult Rat Striatum After Transforming Growth Factor Alpha Infusion & 6-Hydroxydopamine Lesion", (1994) Soc. Neurosci. Abs.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/739,933
Filing Date	December 18, 2000
First Named Inventor	REID, James Steven
Art Unit	1625
Examiner Name	ANDRES, Janet L.
Attorney Docket Number	E8019-00001

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		REID, S., et al. Review of "Trophic regulation of the basal ganglia." J. Chemical Neuroanatomy, 1995; 9(2):79-80	
		REID, S., et al., "Radial Migration of Subependymal Cells in the Adult Rodent Forebrain", (1996) Soc. Neurosci. Abs.	
		VENTRELLA, J., et al., "Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway", J. Neurosurg. (1993); 37:1-8	
		WEISS, S., et al., "Multipoint CNS Stem Cells Are Present in the Adult Mammalian Spinal Cord and Ventricular Neuroaxis", J. Neuroscience (1996); 16(23):7599-7609	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.